Company: SRPT
Filing Date: 2025-03-03
Form Type: S-3ASR
Source: 0001193125-25-044088
Chunk: 7

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-03-03
Form: S-3ASR
Chunk 7
---
 of our product candidates, the expected timing for the reporting of data from on-goingtrials, the structure and outcomes of our planned or pending clinical trials, additional planned studies, and our rights to develop or commercialize our products or product candidates and our ability to fund operations for a specified period of time. Forward-looking statements are not guarantees of future performance and our actual results could differ materially from the results discussed in the forward-looking statements we make. In particular, you should consider the numerous risks described in our most recent Annual Report on Form 10-K,any subsequent Quarterly Reports on Form 10-Qand any Current Reports on Form 8-Kwe file after the date of this prospectus, each as incorporated by reference in this prospectus, and in the “Risk Factors” section in the applicable prospectus supplement. See “Where You Can Find More Information.” As a result of these and other factors, we may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. The forward-looking statements contained in this prospectus reflect our views as of the date hereof. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. USE OF PROCEEDS Unless we state otherwise in the applicable prospectus supplement or free writing prospectus, we intend to use the net proceeds from the sale of the securities for one or more of the following purposes:

| • |     | to fund the continuation and initiation of further clinical trials, commercialization, manufacturing and business 
 development activities;                                                                                           |

2

| • |     | to finance capital expenditures and capacity expansions; and/or |

| • |     | for general corporate purposes and working capital. |

Until we apply the proceeds from a sale of securities to their intended purposes, we may invest these proceeds in highly liquid, investment grade securities. We cannot predict whether the proceeds invested will yield a favorable return. The specific allocations of the proceeds we receive from the sale of our securities and any material amounts of other funds necessary to accomplish the specified purposes for with the proceeds are to be obtained will be described in the applicable prospectus supplement or free writing prospectus. 3

SELLING SECURITYHOLDERS

This prospectus covers the offering for resale of common stock by selling securityholders. Information about such selling securityholders will
be set forth in a prospectus supplement, in an amendment to the registration statement of which this